Obinutuzumab-Induced B Cell Depletion Reduces Spinal Cord Pathology in a CD20 Double Transgenic Mouse Model of Multiple Sclerosis

B cell-depleting therapies have recently proven to be clinically highly successful in the treatment of multiple sclerosis (MS). This study aimed to determine the effects of the novel type II anti-human CD20 (huCD20) monoclonal antibody (mAb) obinutuzumab (OBZ) on spinal cord degeneration in a B cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Breakell, Thomas, Tacke, Sabine, Schropp, Verena, Zetterberg, Henrik, Blennow, Kaj, Urich, Eduard, Kuerten, Stefanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7559311/
https://www.ncbi.nlm.nih.gov/pubmed/32962135
http://dx.doi.org/10.3390/ijms21186864

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7559311/
https://www.ncbi.nlm.nih.gov/pubmed/32962135
http://dx.doi.org/10.3390/ijms21186864

Ejemplares similares